FORTE trial: Minimal residual disease evaluation in newly diagnosed multiple myeloma

Bookmark and Share
Published: 11 Jun 2020
Views: 325
Rating:
Save
Dr Stefania Oliva - GIMEMA, European Myeloma Network, Italy

Dr Stefania Oliva speaks to ecancer about the results of the FORTE trial, presented as part of the ASCO 2020 Virtual Meeting.

The phase III trial looked at multiparameter flow cytometry and next-generation sequencing for minimal residual disease evaluation in newly diagnosed multiple myeloma patients.

Prof Oliva explains how the techniques were used in the trial and reports that the results indicate that both techniques are good, but that longer follow-up is needed.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.